Setareh Seyedkazemi - Sep 15, 2023 Form 4 Insider Report for Adverum Biotechnologies, Inc. (ADVM)

Role
Chief Development Officer
Signature
Setareh Seyedkazemi, by /s/ Ron A. Metzger, Attorney-in-Fact
Stock symbol
ADVM
Transactions as of
Sep 15, 2023
Transactions value $
-$9,429
Form type
4
Date filed
9/18/2023, 06:54 PM
Previous filing
Mar 3, 2023
Next filing
Mar 12, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ADVM Common Stock Sale -$9.23K -6.07K -11.27% $1.52 47.8K Sep 15, 2023 Direct F1, F2
transaction ADVM Common Stock Sale -$201 -130 -0.27% $1.55 47.7K Sep 15, 2023 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported on this Form 4 were effected to satisfy certain tax obligations of the Reporting Person incurred with the vesting and settlement of certain performance stock units.
F2 Includes 6,000 shares purchased on May 20, 2023 pursuant to the Issuer's 2014 Employee Stock Purchase Plan, as amended and restated.

Remarks:

In Reporting Person's Form 4 filed on September 16, 2022, a portion of the footnote 1 disclosure reflected that "(a) 1/3 of the shares met a performance condition on September 14, 2022 (of which 50% of these shares vested immediately and 50% of these shares will vest in six months)." The second 50% of the shares actually vested on the one-year anniversary of September 14, 2022. All other information contained in the footnote is correct.